Log in

NASDAQ:RDNT - RadNet Stock Price, Forecast & News

$19.54
-0.05 (-0.26 %)
(As of 12/12/2019 08:21 AM ET)
Today's Range
$19.42
Now: $19.54
$19.72
50-Day Range
$14.86
MA: $17.44
$20.29
52-Week Range
$9.97
Now: $19.54
$20.42
Volume159,701 shs
Average Volume1.09 million shs
Market Capitalization$982.28 million
P/E Ratio29.61
Dividend YieldN/A
Beta0.96
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$975.15 million
Cash Flow$2.22 per share
Book Value$4.10 per share

Profitability

Net Income$32.24 million

Miscellaneous

Employees7,869
Market Cap$982.28 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.


RadNet (NASDAQ:RDNT) Frequently Asked Questions

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) announced its earnings results on Tuesday, November, 12th. The medical research company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.11 by $0.05. The medical research company earned $292.70 million during the quarter, compared to analyst estimates of $283.39 million. RadNet had a net margin of 3.02% and a return on equity of 16.52%. The company's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 EPS. View RadNet's Earnings History.

When is RadNet's next earnings date?

RadNet is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for RadNet.

What guidance has RadNet issued on next quarter's earnings?

RadNet issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$1.1-1.15 billion, compared to the consensus revenue estimate of $$1.13 billion.

What price target have analysts set for RDNT?

2 equities research analysts have issued twelve-month price targets for RadNet's stock. Their forecasts range from $17.50 to $23.00. On average, they anticipate RadNet's share price to reach $20.25 in the next twelve months. This suggests a possible upside of 3.6% from the stock's current price. View Analyst Price Targets for RadNet.

What is the consensus analysts' recommendation for RadNet?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RadNet.

Has RadNet been receiving favorable news coverage?

News headlines about RDNT stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. RadNet earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for RadNet.

Are investors shorting RadNet?

RadNet saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 1,810,000 shares, an increase of 124.8% from the November 14th total of 805,000 shares. Based on an average trading volume of 464,400 shares, the days-to-cover ratio is presently 3.9 days. Currently, 4.4% of the shares of the stock are sold short. View RadNet's Current Options Chain.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), UnitedHealth Group (UNH), Rigel Pharmaceuticals (RIGL), Alibaba Group (BABA), Baidu (BIDU), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), AbbVie (ABBV), AT&T (T) and Athersys (ATHX).

Who are RadNet's key executives?

RadNet's management team includes the folowing people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division

Who are RadNet's major shareholders?

RadNet's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dalton Greiner Hartman Maher & Co. (2.48%), Beck Mack & Oliver LLC (2.13%), State Street Corp (1.77%), Russell Investments Group Ltd. (1.62%), Tamarack Advisers LP (0.65%) and Cadence Capital Management LLC (0.47%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Institutional Ownership Trends for RadNet.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Moab Capital Partners LLC, Miracle Mile Advisors LLC, Wedge Capital Management L L P NC, Strs Ohio, Barclays PLC, Cadence Capital Management LLC and First Allied Advisory Services Inc.. Company insiders that have sold RadNet company stock in the last year include David L Swartz, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Insider Buying and Selling for RadNet.

Which institutional investors are buying RadNet stock?

RDNT stock was acquired by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Russell Investments Group Ltd., Mackay Shields LLC, Assenagon Asset Management S.A., Essex Investment Management Co. LLC, Dalton Greiner Hartman Maher & Co., State Street Corp and California Public Employees Retirement System. View Insider Buying and Selling for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $19.54.

How big of a company is RadNet?

RadNet has a market capitalization of $982.28 million and generates $975.15 million in revenue each year. The medical research company earns $32.24 million in net income (profit) each year or $0.66 on an earnings per share basis. RadNet employs 7,869 workers across the globe.View Additional Information About RadNet.

What is RadNet's official website?

The official website for RadNet is http://www.radnet.com/.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]


MarketBeat Community Rating for RadNet (NASDAQ RDNT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Commodities

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel